Radioligand 177Lu-PSMA-617 Delays Radiographic Progression in PSMA-Positive Hormone-Sensitive Metastatic Prostate Cancer, Phase 3 Trial Shows
Phase 3 PSMAddition trial found 177Lu‑PSMA‑617 added to hormonal therapy reduced risk of radiographic progression in PSMA‑positive mHSPC.